Syncona Limited Update on Achilles' proposed IPO (5071T)
March 25 2021 - 7:13AM
UK Regulatory
TIDMSYNC
RNS Number : 5071T
Syncona Limited
25 March 2021
Syncona Limited
Update on Achilles' proposed IPO in the United States
25 March 2021
Syncona Ltd, a leading healthcare company focused on founding,
building and funding a portfolio of global leaders in life science,
notes that its portfolio company, Achilles Therapeutics plc
("Achilles") has filed an amended registration statement on Form
F-1 with the U.S. Securities and Exchange Commission (the "SEC")
relating to a proposed initial public offering in the United States
of its American Depositary Shares ("ADSs"), each ADS representing
one ordinary share.
The registration statement discloses an indicative pricing range
for the proposed offering of U.S. $17.00 - $19.00 per ADS. This
would represent an increase in value of Syncona's current
shareholding in Achilles (compared to the sterling holding value
announced on 31 December 2020) of GBP42.9-GBP59.1 million[1]
(6.4.p-8.8p per Syncona share). The proposed offering amount
specified in the filing is 9,750,000 ADSs which at the midpoint of
the indicative pricing range would result in gross proceeds to
Achilles of approximately U.S. $175.5 million and does not include
the underwriters' option to purchase additional ADSs.
A registration statement relating to the securities has been
filed with the Securities and Exchange Commission but has not yet
become effective. The securities may not be sold nor may offers to
buy be accepted prior to the time the registration statement
becomes effective. The registration statement can be accessed
through the SEC's EDGAR database.
This announcement does not constitute an offer to sell or the
solicitation of an offer to buy securities, and shall not
constitute an offer, solicitation or sale in any jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of that
jurisdiction.
The securities referred to in this announcement are to be
offered only by means of a prospectus. Copies of the preliminary
prospectus can be obtained from J.P. Morgan Securities LLC, c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
NY 11717, collect telephone (212) 834-4533, or by email at
prospectus-eq_f@jpmchase.com; from BofA Securities, Attn:
Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd
floor, Charlotte, NC 28255, or by emailing
dg.prospectus-requests@bofa.com; and from Piper Sandler & Co.,
800 Nicollet Mall, J12S03, Minneapolis, MN 55402, Attn: Prospectus
Department, by telephone at (800) 747-3924, or by email at
prospectus@psc.com.
[ENDS]
Enquiries
Syncona Ltd
Annabel Clay
Tel: +44 (0) 20 3981 7940
FTI Consulting
Ben Atwell / Natalie Garland-Collins / Tim Stamper
Tel: +44 (0) 20 3727 1000
About Syncona
Syncona's purpose is to invest to extend and enhance human life.
We do this by founding, building and funding a portfolio of global
leaders in life science, to deliver transformational treatments to
patients in areas of high unmet need.
Our strategy is to found, build and fund companies around
exceptional science to create a dynamic portfolio of 15-20 globally
leading healthcare businesses for the benefit of all our
stakeholders. We focus on developing treatments for patients by
working in close partnership with world-class academic founders and
management teams. Our strategic balance sheet underpins our
strategy enabling us to take a long-term view as we look to improve
the lives of patients with no or few treatment options, build
sustainable life science companies and deliver strong risk-adjusted
returns to shareholders.
[1] All FX as at 24 March 2021
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
PFUPPUGGWUPGGGA
(END) Dow Jones Newswires
March 25, 2021 07:13 ET (11:13 GMT)
Syncona (LSE:SYNC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Syncona (LSE:SYNC)
Historical Stock Chart
From Apr 2023 to Apr 2024